Skip to NavigationSkip to content

FDA green-lights Alembic's cholesterol drug

Published on 15/05/17 at 09:31am

Alembic Pharmaceuticals has announced that its fenofibric acid delayed-release capsules have been approved by the FDA for reducing high cholesterol and increasing good cholesterol.

The capsules are indicated as supplementary to primary therapy in the treatment of high triglyceride in patients with hypertriglyceridemia, as well as to lower high LDL-C levels, total cholesterol, and to increase high-density lipoprotein – also known as ‘good’ cholesterol.

The firm revealed the news via a statement which read: “The company has received US Food and Drug Administration (FDA) approval for its abbreviated new drug application (ANDA) for its Fenofibric Acid Delayed-Release Capsules, 45mg and 135mg.” The capsules are therapeutically equivalent to Abbvie’s Trilipix, the reference listed drug product.

The capsules were approved under an abbreviated new drug application with the FDA; Alembic currently has 56 such approvals with the regulator.  

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches